Factbox-Top cases now before the US Supreme Court
The U.S. Supreme Court's current term includes cases involving TikTok, guns, gender-affirming medical care for transgender ...
FDA will allow Zyn nicotine pouches to stay on the market
Zyn products will be allowed to stay on the market after federal health officials said Thursday that the popular nicotine ...
VERIFYING 4 claims about the FDA ban on red dye No. 3
VERIFY answers four questions about the common food additive red dye No. 3, including what products contain it and if the FDA ...
Targeted Oncology43m
FDA Approves Dato-DXd in HR+, HER2- Breast Cancer Following TROPION-Breast01
Virginia G. Kaklamani, MD, DSc, discusses findings from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan.
BioPharma Dive22m
Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.
Robots the size of rice grains aim to revolutionize brain surgery
Existing solutions often involve stiff, invasive tools that can cause major damage to sensitive brain tissue. Robeauté's bot, ...
BioPharma Dive21m
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.